Intravitreal injection of agents that target vascular endothelial growth factor (VEGF) has provided therapeutic benefit in individuals with nAMD by preventing loss of vision or improving visual acuity, although some patients develop subretinal fibrosis and geographic atrophy during such treatment2,3. Here, VEGFA is linked to atrophic macular degeneration.